← Back to headlines
EyePoint Pharmaceuticals Shares Fall After Clinical Trial Setback and Analyst Downgrade
TD Cowen downgrades the biotech firm's stock following disappointing results in a late-stage clinical trial, triggering a broader market sell-off.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally
44m ago
Pentagon Temporarily Rescinds Mandatory Testosterone Screening Guidance for Troops
1h ago
Experts Warn Obsessive Sleep Tracking May Disrupt Rest Quality
2h ago
UNICEF Reports 20 Million Children Face Annual Online Sexual Abuse
2h ago